26 January 2024 - Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival. ...
24 January 2024 - UroGen Pharma today announced the submission of the Chemistry, Manufacturing, and Controls section of the new drug ...
23 January 2024 - FDA continues to review the file past the Prescription Drug User Fee Act goal date of ...
22 January 2024 - PDUFA goal date is 16 November 2024. ...
22 January 2024 - Botannix Pharmaceuticals’ resubmission of the new drug application for Sofdra has been accepted by the FDA ...
17 January 2024 - Utility has received a Prescription Drug User Fee Act target action date of 24 April 2024. ...
9 January 2024 - Shorla Oncology announced today that the US FDA has accepted for review the company’s new drug application ...
10 January 2024 - Application is supported by data from the pivotal Phase 2b/3 studies evaluating safety and efficacy of long-acting ...
8 January 2024 - Supplement to a new drug submission supported by positive Phase 2 and Phase 3 pivotal trial ...
9 January 2024 - Submission based on positive results from global Phase 3 study demonstrating overall survival benefit of TIVDAK ...
8 January 2024 - Arimoclomol NDA has been assigned a PDUFA action date of 21 June 2024. ...
5 January 2024 - NDA submission supported by positive Phase 3 clinical data. ...
4 January 2024 - Biosimilar for Stelara (ustekinumab) seeks to treat several auto-immune disorders caused by overactive immune response. ...
3 January 2024 - Submissions are based on positive results from Phase 3 registrational ACTION-Galactosemia Kids study demonstrating consistent long-term ...
2 January 2024 - Submission comes on the heels of the recent FDA approval of the Trogarzo intravenous push loading dose. ...